^
Association details:
| Biomarker: | NPM1 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) + Jakafi (ruxolitinib) (JAK2 inhibitor, JAK1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Patterns of Sensitivity Exhibited By Venetoclax-Inclusive Drug Combinations in Acute Myeloid Leukemia
Published date:
11/06/2019
Excerpt:
At the genetic level, Rux+Ven sensitivity included not only specimens harboring the highly frequent FLT3-ITD and NPM1 mutations, but also those with TP53 mutations, which carries a very poor disease prognosis clinically and associated with venetoclax resistance.
DOI:
https://doi.org/10.1182/blood-2019-126020
